We report the case of a man suffering from rheumatoid arthritis, resistant to common OMAROs and anti-TNF-alpha, who received an excellent response, in terms of effectiveness and depletion of C020 positive B-Iymphocytes, to minimal doses of anti-C020 monoclonal antibody (rituximab). The dose used was only 100 mg, repeated after 2 weeks. Already after the first infusion of rituximab, a profound depletion of C020 B-Iymphocytes and an improvement of clinical symptoms were evident. The patient, after 4 months from the first two infusions, maintained an accentuated lymphocyte depletion and obtained a low disease activity, passing from an initial OAS28 of 6.3 to a OAS28 of 2.8. The possible practical implications of this observation are taken into consideration.
The anti-B lymphocyte antigen CD20 monoclonal antibody (rituximab) is already a well experimented molecule in the treatment of rheumatoid arthritis (RA). The commonly used dosage is 1000 mg in two infusions, two weeks apart from each other (I). The course of therapy is usually repeated every 6 months, resulting in a significant and lasting depletion of CD20 B-Iymphocytes, which repopulate on average after about 8 months (2) .
In a recent presentation of a case report (3), we describe the occurrence of significant and prolonged lymphocyte depletion (B CD20 positive) in a woman suffering from RA who, for an allergic reaction to the first infusion ofrituximab, was administered only a small dose of the drug (50 mg). In this woman, the lymphocyte depletion was not accompanied by a simultaneous improvement of clinical symptoms.
We describe the case of a patient affected by RA refractory to common DMARDs and anti-TNF-alpha treated with rituximab at a minimal dose of 100 mg, repeated after two weeks, with which a low disease activity and deep, prolonged lymphocyte depletion was obtained.
Clinical case
A 35-year-old man, suffering from RA from the age of 32, was initially treated with methotrexate (15 mg/week) for about 6 months, without success. A biological therapy (etanercept 50 mg/week) was then added, with which we obtained a good control of the disease for about a year. After that, the patient had a significant resurgence of the disease with severe functional impairment (DAS28: 6.0), so we decided to interrupt etanercept and replace it with infliximab (3 mg/kg). Even with this anti-TNFalpha, no improvements were obtained (DAS28: 6.3). Moreover, a severe infusion reaction occurred at the last dose of infliximab. The decision was then made to start therapy with rituximab which is associated with methotrexate (15 mg/week). The decision to undertake this therapy was also dictated by the fact that the patient had a lymphocyte count characterized by an increase in the percentage of C020 B-lymphocytes. The C020 B-lymphocyte counts were performed using monoclonal antibodies CO 19 and a C045 FlTC/SS gating strategy. The CD 19 lymphocytes in our patient appeared to be 23.6% (range 7.0 to 16.0%) with a total count of 377cells/ul (range 100-400 cells). It was therefore assumed that the C020 lymphocyte subset could have a pathogenetic prevalence in the induction of RA in our patient.
Because of safety concerns related with the previous infliximab reaction, as well as in the light of our earlier experience (3), we decided to treat him with a minimal dose of rituximab (100 mg repeated after 2 weeks) to confirm whether such a low dose of the drug could also lead to a significant lymphocyte depletion and to assess the therapeutic effectiveness. The infusions were preceded by common premedication with methylprednisolone, acetaminophen and chlorphenamine.
One week after the first infusion, the count of lymphocyte populations were repeated and showed a profound depletion of CD 19 B-lymphocytes (0.3% with a total count of 5 cells/ul). One month after the two infusions, the patient presented a marked improvement in joint symptoms and general state of health (OAS28: 3.4).
After 4 months of therapy the patient continues to maintain a low disease activity (OAS28: 2.8) and continues to pose a significant C020 lymphocyte depletion (COI9 0.2%; 8/ul cells).
DISCUSSION
Our first occasional-observation of depletion of C020 B-lymphocytes, withminimal doses of rituximab (3) led us to formulate some questions to which we could not give definite answers.
The first was whether a small dose of rituximab (50 mg), in the light of the profound lymphocyte depletion that it caused, could also have a therapeutic effect. Our case shows that even a minimal dose of the drug may lead to a low disease activity and may still result in a disease control equal to that which can be obtained with the standard recommended dose. This observation should, however, be confirmed by randomized controlled trials (RCT). We cannot exclude that even lower doses of rituximab (i.e. <200 mg as cumulative dose) may be effective, such dose finding requiring a further study.
The second question regarded the possibility that the peripheral lymphocyte depletion could be accompanied by a simultaneous depletion even at the synovial level. We can not give an answer to this question, but the disease control obtained could suggest a depletive action even at the synovial level.
The third question was related to the event that the patient had an allergic reaction and we wondered if the lymphocyte depletion was not secondary to a broader idiosyncrasy of the patient to the drug. The description of this other case shows that the drug, without a doubt, leads to a profound and prolonged lymphocyte depletion equal to the much higher doses that are recommended, regardless of any condition of the patient's idiosyncrasy. The practical implications of this observation may be important.
First of all, such a low dose of Rituximab may be associated with a lower risk of adverse events related to the drug, such as an allergic reaction to the first infusion or the most dangerous, but rare, cytokine release syndrome (4) .
Secondly, with such a low dose there is a significant savings in costs that can be programmed into the budget in order to treat a greater amount of patients with biologics.
Thirdly, the data is of particular importance from a therapeutic point of view. Without doubt, the drug is a potent inhibitor of C020 B-lymphocytes, even at low doses. This observation should open further testing and RCT for confirmation of the curative properties of rituximab on RA, even at the minimal doses (100 mg x 2 ) that we tested. Indeed, so far, the drug in the treatment of RA has been tested in an RCT only at a dose not less than 500 mg x 2, which showed an identical effectiveness to the standard dose of 1000 mg x 2 (5).
In conclusion, our case report confirms our previous observation that minimal doses ofrituximab (100 mg) reduce C020 B-lymphocytes in a profound and prolonged way. At the same time, a dose of 100 mg x 2 alone can control disease activity.
However, we are still without a definite answer to the question as to whether the proven peripheral lymphocyte depletion corresponds to an equally important and lasting depletion at the synovial level.
